Drug
Trebananib clinical trials
Also written AMG 386.
- studies test it
- 29
- open now
- 1
- in phase 3
- 2
- first study started
- 2005
Keep track of what changes. Save the trebananib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AMG 386
- 23
Studies by the year they started
28 studies that test it; most in 2012 (8)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 8 |
| 2014 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 15
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 11
Amgen (17) · National Cancer Institute (NCI) (5) · Dana-Farber Cancer Institute (1) · Roswell Park Cancer Institute (1) · Gynecologic Oncology Group (1) · Takeda (1) · QuantumLeap Healthcare Collaborative (1) · Austin Health (1)
Often tested with
Tested in the same studies.
Paclitaxel (4) · Bevacizumab (3) · Pembrolizumab (2) · Sunitinib (2) · Sorafenib (2) · Cytarabine (1) · Motesanib diphosphate (1) · Carboplatin (1)
Studies
Open first, then newest update. How each study uses trebananib is read from its arms, and is right about nine times in ten.
Testing it · 29
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as AMG 386 and Trastuzumab
- Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorCompletedPhase 1Dana-Farber Cancer InstituteNCT03239145Written as Trebananib
- Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast CancerCompletedPhase 1AmgenNCT00807859Written as AMG 386 30 mg/kg, Paclitaxel and Trastuzumab
- Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedPhase 1Roswell Park Cancer InstituteNCT01555268Written as trebananib
- Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain TumorsCompletedPhase 2National Cancer Institute (NCI)NCT01609790Written as Trebananib
- AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With SunitinibCompletedPhase 2AmgenNCT00853372Written as Trebananib
- Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal CancerCompletedPhase 2AmgenNCT00479817Written as AMG 386
- AMG 386 and Abiraterone for Advanced Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT01553188Written as AMG 386
- Trebananib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedPhase 2Gynecologic Oncology GroupNCT01210222Written as Trebananib
- A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal FunctionCompletedPhase 1AmgenNCT01331941Written as AMG 386 + Paclitaxel
- TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian CancerTerminatedPhase 3AmgenNCT01493505Written as AMG 386
- To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.CompletedPhase 1AmgenNCT00861419Written as AMG 386
- TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube CancerCompletedPhase 3AmgenNCT01204749Written as AMG 386
- Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01538095Written as Trebananib
- Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung CancerCompletedPhase 1/2AmgenNCT01666977Written as AMG 386
- A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular CancerCompletedPhase 2AmgenNCT00872014Written as AMG 386
- AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With SorafenibCompletedPhase 2AmgenNCT00467025Written as AMG 386
- Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer PatientsCompletedPhase 2AmgenNCT00511459Written as AMG 386
- Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by SurgeryCompletedPhase 2National Cancer Institute (NCI)NCT01623869Written as Trebananib
- Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian CancerCompletedPhase 1AmgenNCT01253681Written as AMG 386, paclitaxel and carboplatin
See all 29 studies that test trebananib →
Given in every arm · 2 — trebananib is usual care beside what is tested
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney CancerCompletedPhase 2National Cancer Institute (NCI)NCT01664182Written as Trebananib
- Amgen 386 for Recurrent GlioblastomaCompletedPhase 1/2Dana-Farber Cancer InstituteNCT01290263Written as Amgen 386
Codes
What other systems call trebananib · ClinicalTrials.gg INT005678
- MeSH (NLM) C551398trebananibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) X8Y5U6NC7ETREBANANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q104268400trebananibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91711TrebananibOne source FDA
- DrugBank DB12056One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C551398 | trebananib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | X8Y5U6NC7E | TREBANANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q104268400 | trebananib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91711 | Trebananib | One source FDA |
| DrugBank | DB12056 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.